480 related articles for article (PubMed ID: 27825122)
1. Identification and validation of differentially expressed proteins in epithelial ovarian cancers using quantitative proteomics.
Qu H; Chen Y; Cao G; Liu C; Xu J; Deng H; Zhang Z
Oncotarget; 2016 Dec; 7(50):83187-83199. PubMed ID: 27825122
[TBL] [Abstract][Full Text] [Related]
2. MCT1 promotes the cisplatin-resistance by antagonizing Fas in epithelial ovarian cancer.
Yan C; Yang F; Zhou C; Chen X; Han X; Liu X; Ma H; Zheng W
Int J Clin Exp Pathol; 2015; 8(3):2710-8. PubMed ID: 26045776
[TBL] [Abstract][Full Text] [Related]
3. HOTAIR is a potential target for the treatment of cisplatin‑resistant ovarian cancer.
Wang Y; Wang H; Song T; Zou Y; Jiang J; Fang L; Li P
Mol Med Rep; 2015 Aug; 12(2):2211-6. PubMed ID: 25824616
[TBL] [Abstract][Full Text] [Related]
4. Knockdown of MACC1 expression increases cisplatin sensitivity in cisplatin-resistant epithelial ovarian cancer cells.
Zhang R; Shi H; Ren F; Li X; Zhang M; Feng W; Jia Y
Oncol Rep; 2016 Apr; 35(4):2466-72. PubMed ID: 26794135
[TBL] [Abstract][Full Text] [Related]
5. FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells.
Chiu WT; Huang YF; Tsai HY; Chen CC; Chang CH; Huang SC; Hsu KF; Chou CY
Oncotarget; 2015 Feb; 6(4):2349-65. PubMed ID: 25537512
[TBL] [Abstract][Full Text] [Related]
6. Association of Sp1 and survivin in epithelial ovarian cancer: Sp1 inhibitor and cisplatin, a novel combination for inhibiting epithelial ovarian cancer cell proliferation.
Sankpal UT; Ingersoll SB; Ahmad S; Holloway RW; Bhat VB; Simecka JW; Daniel L; Kariali E; Vishwanatha JK; Basha R
Tumour Biol; 2016 Oct; 37(10):14259-14269. PubMed ID: 27581819
[TBL] [Abstract][Full Text] [Related]
7. Association of expression of XIAP-associated factor 1 (XAF1) with clinicopathologic factors, overall survival, microvessel density and cisplatin-resistance in ovarian cancer.
Wang Y; Mao H; Hao Q; Wang Y; Yang Y; Shen L; Huang S; Liu P
Regul Pept; 2012 Oct; 178(1-3):36-42. PubMed ID: 22759793
[TBL] [Abstract][Full Text] [Related]
8. [Cisplatin resistant effects of dihydrofolate reductase gene expression up-regulation in epithelial ovarian cancer].
Li Z; Wang Q; Zhang W; Yang Z; Li L
Zhonghua Fu Chan Ke Za Zhi; 2015 Nov; 50(11):854-60. PubMed ID: 26887775
[TBL] [Abstract][Full Text] [Related]
9. IL-6R/STAT3/miR-204 feedback loop contributes to cisplatin resistance of epithelial ovarian cancer cells.
Zhu X; Shen H; Yin X; Long L; Chen X; Feng F; Liu Y; Zhao P; Xu Y; Li M; Xu W; Li Y
Oncotarget; 2017 Jun; 8(24):39154-39166. PubMed ID: 28388577
[TBL] [Abstract][Full Text] [Related]
10. miR-100 resensitizes resistant epithelial ovarian cancer to cisplatin.
Guo P; Xiong X; Zhang S; Peng D
Oncol Rep; 2016 Dec; 36(6):3552-3558. PubMed ID: 27748936
[TBL] [Abstract][Full Text] [Related]
11. CLIC1 a novel biomarker of intraperitoneal metastasis in serous epithelial ovarian cancer.
Ye Y; Yin M; Huang B; Wang Y; Li X; Lou G
Tumour Biol; 2015 Jun; 36(6):4175-9. PubMed ID: 25582317
[TBL] [Abstract][Full Text] [Related]
12. Tribbles 2 mediates cisplatin sensitivity and DNA damage response in epithelial ovarian cancer.
Kritsch D; Hoffmann F; Steinbach D; Jansen L; Mary Photini S; Gajda M; Mosig AS; Sonnemann J; Peters S; Melnikova M; Thomale J; Dürst M; Runnebaum IB; Häfner N
Int J Cancer; 2017 Oct; 141(8):1600-1614. PubMed ID: 28670762
[TBL] [Abstract][Full Text] [Related]
13. Exon 4 deletion variant of epidermal growth factor receptor enhances invasiveness and cisplatin resistance in epithelial ovarian cancer.
Zhang P; Zhang P; Zhou M; Jiang H; Zhang H; Shi B; Pan X; Gao H; Sun H; Li Z
Carcinogenesis; 2013 Nov; 34(11):2639-46. PubMed ID: 23764753
[TBL] [Abstract][Full Text] [Related]
14. The role of RhoC in ovarian epithelial carcinoma: a marker for carcinogenesis, progression, prognosis, and target therapy.
Zhao Y; Zheng HC; Chen S; Gou WF; Xiao LJ; Niu ZF
Gynecol Oncol; 2013 Sep; 130(3):570-8. PubMed ID: 23764197
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-137 suppresses tumor growth in epithelial ovarian cancer in vitro and in vivo.
Zhang L; Li Z; Gai F; Wang Y
Mol Med Rep; 2015 Aug; 12(2):3107-14. PubMed ID: 25955305
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-145 targets TRIM2 and exerts tumor-suppressing functions in epithelial ovarian cancer.
Chen X; Dong C; Law PT; Chan MT; Su Z; Wang S; Wu WK; Xu H
Gynecol Oncol; 2015 Dec; 139(3):513-9. PubMed ID: 26472353
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of RIF1 Enhances Sensitivity to Platinum-Based Chemotherapy in Epithelial Ovarian Cancer (EOC) by Regulating Nucleotide Excision Repair (NER) Pathway.
Liu YB; Mei Y; Tian ZW; Long J; Luo CH; Zhou HH
Cell Physiol Biochem; 2018; 46(5):1971-1984. PubMed ID: 29719287
[TBL] [Abstract][Full Text] [Related]
18. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
19. NANOG regulates epithelial-mesenchymal transition and chemoresistance in ovarian cancer.
Qin S; Li Y; Cao X; Du J; Huang X
Biosci Rep; 2017 Feb; 37(1):. PubMed ID: 27884977
[TBL] [Abstract][Full Text] [Related]
20. 4-Acetylantroquinonol B suppresses autophagic flux and improves cisplatin sensitivity in highly aggressive epithelial cancer through the PI3K/Akt/mTOR/p70S6K signaling pathway.
Liu M; Bamodu OA; Huang WC; Zucha MA; Lin YK; Wu ATH; Huang CC; Lee WH; Yuan CC; Hsiao M; Deng L; Tzeng YM; Yeh CT
Toxicol Appl Pharmacol; 2017 Jun; 325():48-60. PubMed ID: 28408137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
